Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06098651 · ClinicalTrials.gov registry record · Phase 1
A Study of DCR-STAT3 in Adults With Solid Tumors
A Phase 1 study of Solid Tumor, Adult and Refractory Tumor, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT06098651 is a Phase 1 study of Solid Tumor, Adult and Refractory Tumor that has completed, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 26 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06098651, a Phase 1 study of Solid Tumor, Adult and Refractory Tumor, has completed, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
Conditions Studied
Interventions
- DRUG DCR-STAT3
Study Locations (2)
Texas
- Next Oncology - Dallas
- Next Oncology - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2025-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06098651
The ClinicalTrials.gov registry entry for NCT06098651 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (86% lower). The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which DCR-STAT3 is the first listed.
NCT06098651 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06098651 about?
NCT06098651 is a clinical study titled "A Study of DCR-STAT3 in Adults With Solid Tumors". This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
What is the current status of trial NCT06098651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-08-14. Estimated completion is 2025-09-17.
What conditions does trial NCT06098651 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, Refractory Tumor.
What interventions are being tested in trial NCT06098651?
The interventions under investigation include: DCR-STAT3 (DRUG).
Who is sponsoring clinical trial NCT06098651?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06098651 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.